Ishita Drugs and Industries Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The certificate pertains to the quarter ended March 31, 2026, and was submitted on April 10, 2026.

Regulatory Compliance Details

The certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly reporting on dematerialization activities. The document was prepared by Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent (RTA).

Certificate Confirmation

Bigshare Services Private Limited confirmed in their certificate dated March 31, 2026, that no securities were received from depository participants for dematerialization during the quarter from December 31, 2025 to March 31, 2026. Consequently, no certificates were mutilated and cancelled, and no substitution of depositories' names occurred in the register of members.

The RTA's confirmation specifically states that since there were no securities for dematerialization, there was no requirement for certificate substitution within the mandated 15-day period as per regulatory guidelines.

Corporate Information

The submission was signed by Jagdish Agrawal, Managing Director (DIN: 01031687), on behalf of Ishita Drugs and Industries Limited. The company operates with its corporate office located at 401, 3rd Eye II, Opposite Parimal Garden, C.G. Road, Ahmedabad-380006, and its registered office and factory at 179/1, Vasna-Iyava, Tal. Sanand, District Ahmedabad.

Regulatory Framework

This certificate submission aligns with SEBI circulars NSDL/CIR/II/5/2019 and CDSL/OPS/RTA/POLICY/2019/14, both dated January 25, 2019, along with SEBI letter reference MRD/DOP2/DSA2/OW/2019/2498/1 dated January 24, 2019. These regulations ensure transparency in dematerialization processes and maintain accurate records of securities transactions.

Ishita drugs & indus has disclosed another share acquisition by its related party under SEBI regulations. Ishita Pharmaceuticals, identified as a related party of the target company, acquired an additional 390 equity shares of Rs. 10 each on February 26, 2026, following its previous acquisition of 506 shares on February 24, 2026. Both transactions were conducted through open market purchases and disclosed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Recent Transaction Details

The latest acquisition involved a purchase of 390 shares that further increased Ishita Pharmaceuticals' stake in the company. The disclosure was filed with BSE Limited, where Ishita Drugs & Industries shares are listed under scrip code 524400.

Updated Shareholding Position

The recent acquisition has resulted in a further increase in Ishita Pharmaceuticals' ownership percentage. Prior to this latest transaction, the related party held 32,252 shares representing 1.08% of the total share capital. Post-acquisition, the holding increased to 32,642 shares, representing 1.09% of the company's equity.

Company Capital Structure

The target company's equity share capital remained unchanged following both acquisitions. Ishita Drugs & Industries maintains its total equity share capital at Rs. 29,903,000, divided into 2,990,300 equity shares of Rs. 10 each. The diluted share capital also remains at the same level, indicating no outstanding convertible securities or warrants.

Regulatory Compliance

Both Ishita Drugs & Industries and Ishita Pharmaceuticals filed the necessary disclosures with BSE Limited as required under SEBI regulations. The disclosure format included comprehensive details about the acquirer's holdings before and after each transaction, acquisition mode, and the target company's capital structure. The related party status of Ishita Pharmaceuticals was clearly identified in both regulatory filings, ensuring transparency in the transaction disclosures.